Cargando…

Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction

BACKGROUND: In the setting of myocardial infarction (MI) or acute coronary syndrome (ACS), current guidelines recommend early and aggressive lipid lowering therapy with statins, irrespective of the baseline lipoprotein levels. Takotsubo cardiomyopathy (TCM) patients have a clinical presentation simi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaddam, Sainath, Nimmagadda, Krishna C, Nagrani, Tarun, Naqi, Muniba, Wetz, Robert V, Weiserbs, Kera F, McCord, Donald, Ghavami, Foad, Gala, Bhavesh, Lafferty, James C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094218/
https://www.ncbi.nlm.nih.gov/pubmed/21527016
http://dx.doi.org/10.1186/1755-7682-4-14
_version_ 1782203519492685824
author Gaddam, Sainath
Nimmagadda, Krishna C
Nagrani, Tarun
Naqi, Muniba
Wetz, Robert V
Weiserbs, Kera F
McCord, Donald
Ghavami, Foad
Gala, Bhavesh
Lafferty, James C
author_facet Gaddam, Sainath
Nimmagadda, Krishna C
Nagrani, Tarun
Naqi, Muniba
Wetz, Robert V
Weiserbs, Kera F
McCord, Donald
Ghavami, Foad
Gala, Bhavesh
Lafferty, James C
author_sort Gaddam, Sainath
collection PubMed
description BACKGROUND: In the setting of myocardial infarction (MI) or acute coronary syndrome (ACS), current guidelines recommend early and aggressive lipid lowering therapy with statins, irrespective of the baseline lipoprotein levels. Takotsubo cardiomyopathy (TCM) patients have a clinical presentation similar to myocardial infarction and thus receive early and aggressive statin therapy during their initial hospitalization. However, the pathology of TCM is not atherosclerotic coronary artery disease and hence we assumed the lipid profiles in TCM would be healthier than coronary artery disease patients. METHODS: In this retrospective study, we assessed fasting serum lipoprotein levels of ten TCM patients and compared them with forty, age and sex-matched myocardial infarction (MI) patients. RESULTS: Comparing serum lipoprotein levels of TCM with MI group, there was no significant difference in mean total cholesterol between the two groups (174.5 mg/dL vs. 197.6 mg/dL, p = 0.12). However, in the TCM group, mean HDL-C was significantly higher (66.87 mg/dL vs. 36.5 mg/dL, p = 0.008), the mean LDL-C was significantly lower (89.7 mg/dL vs. 128.9 mg/dL, p = 0.0002), and mean triglycerides was also significantly lower (65.2 mg/dL vs. 166.8 mg/dL, p < 0.0001). CONCLUSIONS: In this study, TCM patients in comparison to MI patients had significantly higher levels of HDL-C, lower levels of LDL-C levels and triglycerides. The lipid profiles in TCM were consistent with the underlying pathology of non-atherosclerotic, non-obstructive coronary artery disease. As lipoproteins in most TCM patients were within the optimal range, we recommend an individual assessment of lipid profiles along with their coronary heart disease risk factors for considering long term lipid-lowering therapy. A finding of hyperalphalipoproteinemia or hypotriglyceridemia in 40% of TCM patients is novel but this association needs to be confirmed in future studies with larger sample sizes. These findings may provide clues in understanding the pathogenesis of takotsubo cardiomyopathy.
format Text
id pubmed-3094218
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30942182011-05-14 Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction Gaddam, Sainath Nimmagadda, Krishna C Nagrani, Tarun Naqi, Muniba Wetz, Robert V Weiserbs, Kera F McCord, Donald Ghavami, Foad Gala, Bhavesh Lafferty, James C Int Arch Med Original Research BACKGROUND: In the setting of myocardial infarction (MI) or acute coronary syndrome (ACS), current guidelines recommend early and aggressive lipid lowering therapy with statins, irrespective of the baseline lipoprotein levels. Takotsubo cardiomyopathy (TCM) patients have a clinical presentation similar to myocardial infarction and thus receive early and aggressive statin therapy during their initial hospitalization. However, the pathology of TCM is not atherosclerotic coronary artery disease and hence we assumed the lipid profiles in TCM would be healthier than coronary artery disease patients. METHODS: In this retrospective study, we assessed fasting serum lipoprotein levels of ten TCM patients and compared them with forty, age and sex-matched myocardial infarction (MI) patients. RESULTS: Comparing serum lipoprotein levels of TCM with MI group, there was no significant difference in mean total cholesterol between the two groups (174.5 mg/dL vs. 197.6 mg/dL, p = 0.12). However, in the TCM group, mean HDL-C was significantly higher (66.87 mg/dL vs. 36.5 mg/dL, p = 0.008), the mean LDL-C was significantly lower (89.7 mg/dL vs. 128.9 mg/dL, p = 0.0002), and mean triglycerides was also significantly lower (65.2 mg/dL vs. 166.8 mg/dL, p < 0.0001). CONCLUSIONS: In this study, TCM patients in comparison to MI patients had significantly higher levels of HDL-C, lower levels of LDL-C levels and triglycerides. The lipid profiles in TCM were consistent with the underlying pathology of non-atherosclerotic, non-obstructive coronary artery disease. As lipoproteins in most TCM patients were within the optimal range, we recommend an individual assessment of lipid profiles along with their coronary heart disease risk factors for considering long term lipid-lowering therapy. A finding of hyperalphalipoproteinemia or hypotriglyceridemia in 40% of TCM patients is novel but this association needs to be confirmed in future studies with larger sample sizes. These findings may provide clues in understanding the pathogenesis of takotsubo cardiomyopathy. BioMed Central 2011-04-28 /pmc/articles/PMC3094218/ /pubmed/21527016 http://dx.doi.org/10.1186/1755-7682-4-14 Text en Copyright ©2011 Gaddam et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Gaddam, Sainath
Nimmagadda, Krishna C
Nagrani, Tarun
Naqi, Muniba
Wetz, Robert V
Weiserbs, Kera F
McCord, Donald
Ghavami, Foad
Gala, Bhavesh
Lafferty, James C
Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
title Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
title_full Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
title_fullStr Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
title_full_unstemmed Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
title_short Serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
title_sort serum lipoprotein levels in takotsubo cardiomyopathy vs. myocardial infarction
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094218/
https://www.ncbi.nlm.nih.gov/pubmed/21527016
http://dx.doi.org/10.1186/1755-7682-4-14
work_keys_str_mv AT gaddamsainath serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT nimmagaddakrishnac serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT nagranitarun serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT naqimuniba serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT wetzrobertv serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT weiserbskeraf serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT mccorddonald serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT ghavamifoad serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT galabhavesh serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction
AT laffertyjamesc serumlipoproteinlevelsintakotsubocardiomyopathyvsmyocardialinfarction